Andreas Kremer is the Head of Hepatology at the Department of Gastroenterology and Hepatology, University Hospital Zurich in Zurich, Switzerland. Professor Kremer is internationally recognized as a clinician, educator and researcher in liver disease. His translational, clinical and experimental research is focused on molecular mechanisms of immune-mediated and cholestatic liver disease including symptom burden such as fatigue and pruritus, fibrogenesis and development of hepatocellular carcinoma. Prof. Kremer has been awarded several national and international research prizes including the Schering-Plough of the Dutch Society of Gastroenterology. His scholarly work has been cited more than 6,500 times (h-index: 42), according to Google Scholar, and he is a member of editorial boards for various journals. He served as a chair for several national and international guidelines, is a member of the Board of Directors of the Swiss Association for the Study of the Liver (SASL) and Chair of International Forum for the Study of Itch special interest group for systemic pruritus.

Disclosures

Consultant, advisor and Speaker fees: Abbvie, Advanz, Alentis, AlphaSigma, AstraZenca, Avior, Bayer, BioNTech, CymaBay, Eisai, Escient, Falk, FMC, Gilead, GSK, Guidepoint, Intercept, Ipsen, Mirum, Medscape, MSD, Myr, Roche, Takeda and Viofor.

Marlyn Mayo received her medical degree from Baylor College of Medicine and completed internship and residency in Internal Medicine at University of California, Irvine. She completed fellowships in Gastroenterology and Hepatology at the University of Texas Southwestern Medical Center at Dallas, where she is currently a Professor in the Department of Internal Medicine, Division of Digestive and Liver Diseases. Dr. Mayo is recognized internationally for her expertise in autoimmune liver diseases, particularly primary biliary cholangitis (PBC). She has been the recipient of numerous grants to study the pathophysiology and treatment of PBC and its symptoms from the National Institute of Health, American Liver Foundation and the pharmaceutical industry. She has published over 100 original scientific articles, review articles, and book chapters on the subject of autoimmune and cholestatic liver disease and its complications.

Disclosures

Grant/Research Support: CymaBay, Ipsen, Glaxo-Smith Kline, Mirum

Consultant/Advisory Board: CymaBay, Glaxo-Smith Kline, Ipsen

Mitchell L Shiffman, MD is the Director of the Liver Institute of Virginia, at Bon Secours Mercy Health in Richmond Virginia. Prior to this Dr Shiffman was the Chief of the Hepatology Section and Medical Director of the Liver Transplant Program at VCU Medical Center from 1999-2009.

Dr Shiffman has published over 300 original articles in peer reviewed medical journals or as invited reviews. He has edited 3 textbooks on liver disease and was a guest editor for 2 volumes of Clinics in Liver Disease. He was a member of the Board of Trustees of the American College of Gastroenterology from 2003-2009. He is a Master of the American College of Gastroenterology and a Fellow of the American Association for the Study of Liver Disease.

Disclosures

To be confirmed.

Marios Nikolaidis, Ph.D., is a Postdoctoral Research Fellow in the Department of Gastroenterology and Hepatology at Mayo Clinic, Rochester, Minnesota, in the laboratory of Dr. Konstantinos Lazaridis. He earned his Ph.D. in Bioinformatics from the University of Thessaly, Greece, and has nearly a decade of experience in bioinformatics, with a primary focus on pathogen genomics. His current research involves collaborative work with Dr. Lazaridis on PSC and PBC.

Disclosures

To be confirmed.